机器人辅助全髋关节置换术是否具有增量价值:469万例全国性 outcomes、趋势与预测分析
该研究基于美国国家住院患者样本(2008–2017)比较机器人臂辅助(RA-THA)、计算机辅助(CA-THA)与手动(M-THA)全髋关节置换术的住院指标、使用趋势及未来预测。倾向评分匹配后,RA-THA与M-THA相比住院时间无临床意义的缩短,非家庭出院率相似,植入物相关机械并发症和住院脱位率更低,但住院费用更高;预测2025年RA-THA占全部THA的23.9%,2030年达65.8%。
要点
- RA-THA相比M-THA植入物相关机械并发症更低(0.5% vs 3.1%,p<0.001),住院脱位率更低(0.1% vs 0.8%,p<0.001)。
- RA-THA住院费用高于M-THA($18,416 vs $17,266,p<0.001),CA-THA也高于M-THA($20,295 vs $18,624,p<0.001)。
- 预测2028年RA-THA使用率可能超过M-THA(48.3%),2030年达全部THA的65.8%。
核心结论
- 技术辅助THA尤其是RA-THA可能通过降低住院早期脱位率及其他住院指标提供价值,但更高的索引手术和住院费用需进一步全面成本分析以确定真实增量价值。
研究设计与样本
- 回顾性全国性数据库分析,查询美国国家住院患者样本(National Inpatient Sample)2008至2017年初次全髋关节置换术,分为RA-THA、CA-THA和M-THA三组,采用倾向评分匹配比较M-THA与RA-THA及M-THA与CA-THA的住院指标,并分析使用趋势与预测。
主要发现
- RA-THA与匹配M-THA相比平均住院时间无临床意义缩短(2.2天(SD 1.4) vs 2.3天(SD 1.8),p<0.001)。
- CA-THA与匹配M-THA相比平均住院时间也无临床意义缩短(2.5天(SD 1.9) vs 2.7天(SD 2.3),p<0.001)。
- RA-THA非家庭出院率与M-THA相似(17.4% vs 18.5%,p=0.205),而CA-THA非家庭出院率低于M-THA(18.7% vs 24.9%,p<0.001)。
- RA-THA植入物相关机械并发症低于M-THA(0.5% vs 3.1%,p<0.001),CA-THA也低于M-THA(1.2% vs 2.2%,p<0.001)。
- RA-THA住院脱位率低于M-THA(0.1% vs 0.8%,p<0.001)。
关键数值与推荐
- RA-THA平均住院费用$18,416(SD $8,048)高于M-THA $17,266(SD $8,396),p<0.001。
- CA-THA平均住院费用$20,295(SD $8,975)高于M-THA $18,624(SD $9,226),p<0.001。
- 预测2025年全部THA中RA-THA占23.9%,CA-THA占3.2%。
- 预测RA-THA使用率可能在2028年超过M-THA(48.3%),2030年达全部THA的65.8%。
临床怎么用
- RA-THA可降低住院早期脱位和植入物相关机械并发症,但住院时间缩短有限且费用更高,临床决策需权衡早期并发症优势与成本。
- 鉴于预测RA-THA使用率快速增长,需进一步开展全面成本分析以评估其在诊疗全程中的真实增量价值。
局限性
- 原文未报告(基于摘要信息,研究为回顾性数据库分析,可能存在编码偏倚和未测量混杂,但摘要未明确列出局限性)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The current study aimed to compare robotic arm-assisted (RA-THA), computer-assisted (CA-THA), and manual (M-THA) total hip arthroplasty regarding in-hospital metrics including length of stay (LOS), discharge disposition, in-hospital complications, and cost of RA-THA versus M-THA and CA-THA versus M-THA, as well as trends in use and uptake over a ten-year period, and future projections of uptake and use of RA-THA and CA-THA. METHODS: The National Inpatient Sample was queried for primary THAs (2008 to 2017) which were categorized into RA-THA, CA-THA, and M-THA. Past and projected use, demographic characteristics distribution, income, type of insurance, location, and healthcare setting were compared among the three cohorts. In-hospital complications, LOS, discharge disposition, and in-hospital costs were compared between propensity score-matched cohorts of M-THA versus RA-THA and M-THA versus CA-THA to adjust for baseline characteristics and comorbidities. RESULTS: RA-THA and CA-THA did not exhibit any clinically meaningful reduction in mean LOS (RA-THA 2.2 days (SD 1.4) vs 2.3 days (SD 1.8); p < 0.001, and CA-THA 2.5 days (SD 1.9) vs 2.7 days (SD 2.3); p < 0.001, respectively) compared to their respective propensity score-matched M-THA cohorts. RA-THA, but not CA-THA, had similar non-home discharge rates to M-THA (RA-THA 17.4% vs 18.5%; p = 0.205, and 18.7% vs 24.9%; p < 0.001, respectively). Implant-related mechanical complications were lower in RA-THA (RA-THA 0.5% vs M-THA 3.1%; p < 0.001, and CA-THA 1.2% vs M-THA 2.2%; p < 0.001), which was associated with a significantly lower in-hospital dislocation (RA-THA 0.1% vs M-THA 0.8%; p < 0.001). Both RA-THA and CA-THA demonstrated higher mean higher index in-hospital costs (RA-THA $18,416 (SD $8,048) vs M-THA $17,266 (SD $8,396); p < 0.001, and CA-THA $20,295 (SD $8,975) vs M-THA $18,624 (SD $9,226); p < 0.001, respectively). Projections indicate that 23.9% and 3.2% of all THAs conducted in 2025 will be robotic arm- and computer-assisted, respectively. Projections indicated that RA-THA use may overtake M-THA by 2028 (48.3%) and reach 65.8% of all THAs by 2030. CONCLUSION: Technology-assisted THA, particularly RA-THA, may provide value by lowering in-hospital early dislocation rates and and other in-hospital metrics compared to M-THA. Higher index-procedure and hospital costs warrant further comprehensive cost analyses to determine the true added value of RA-THA in the episode of care, particularly since we project that one in four THAs in 2025 and two in three THA by 2030 will use RA-THA technology. Cite this article: Bone Joint J 2021;103-B(9):1488-1496.
引用
- Emara AK, Zhou G, Klika AK, et al. Is there increased value in robotic arm-assisted total hip arthroplasty? : a nationwide outcomes, trends, and projections analysis of 4,699,894 cases. Bone Joint J. 2021. PMID: 34465149. doi:10.1302/0301-620X.103B9.BJJ-2020-2411.R1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。